Burgdorf – Terumo Corporation (Terumo), a leading global manufacturer and distributor of medical devices, will fill its PLAJEX™ syringe with the drug Hulio® and assemble it with the YpsoMate prefilled autoinjector from Ypsomed. Hulio® is a biosimilar to Humira® (adalimumab) developed by Fujifilm Kyowa Kirin Biologics Co., Ltd. and marketed in the European Union by Mylan N.V. The drug is used in the treatment of various chronic autoimmune diseases.
The pre-filled autoinjector is based on Ypsomed's YpsoMate platform and is designed for subcutaneous injection of liquid drugs. Terumo assembles the YpsoMate with its proprietary PLAJEX™ syringe for administration of the drug Hulio® with the active ingredient adalimumab. Hulio® received market approval in the European Union in September 2018.
The first commercial deliveries of the YpsoMate from Switzerland to Japan are already completed. Terumo built up its stock in order to support the Hulio® launch.
For Ypsomed, this not only means the successful commercialisation of Hulio® project launched in 2013, but also the first commercial market entry of the YpsoMate autoinjector. Terumo opted for a customer-specific variant of the 1.0 ml autoinjector with a break-proof polymer PLAJEX™ syringe instead of the standard glass syringe.
For Terumo, we have realised a customer-specific design with key features such as a round-shaped body design for a comfortable grip. This is an example of how we can adapt our platform products to specific requirements and thus provide our customers with genuine unique selling points,
comments Ulrike Bauer, Senior Vice President Ypsomed Delivery Systems.
About Terumo Corporation
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers, with over US$ 5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices, including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician-office use. Terumo contributes to society by providing valued products and services to the healthcare market, and by responding to the needs of healthcare providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange and is a component of the Nikkei 225, Japan's leading stock index.
About Fujifilm Kyowa Kirin Biologics
Fujifilm Kyowa Kirin Biologics was established by FUJIFILM Corporation (President: Kenji Sukeno; hereinafter “Fujifilm”) and Kyowa Hakko Kirin Co., Ltd. (President and COO: Masashi Miyamoto, hereinafter “Kyowa Hakko Kirin”) on March 27, 2012 as a company for developing, manufacturing, and marketing biosimilars. Its pipeline includes an adalimumab biosimilar (Product Code: FKB327) and a biosimilar of the anti-VEGF humanized monoclonal antibody bevacizumab (Product Code: FKB238), a drug used to treat a range of cancers including colorectal and non-small cell lung cancer. Fujifilm Kyowa Kirin Biologics established Centus Biotherapeutics Ltd., a joint venture for the development and commercialization of FKB238 with AstraZeneca plc.
By merging the technologies in advanced production, quality control and analysis which Fujifilm has developed over many years through its photographic film business, with the proprietary technologies and know-how which Kyowa Hakko Kirin has accumulated through its biopharmaceutical R&D and manufacturing, Fujifilm Kyowa Kirin Biologics creates revolutionary production processes and reduces costs for the production of biosimilars. Through this partnership, the company will develop and manufacture reliable, high quality, cost-competitive biosimilar products and commercialize these products in a timely manner. With this strategy, Fujifilm Kyowa Kirin Biologics aims to hold a leading position in the expanding biosimilar market.
You can learn more about the business at: fujifilmkyowakirin-biologics.com
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what’s right, not what’s easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which more than 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world’s largest producers of active pharmaceutical ingredients. Every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com. We routinely post information that may be important to investors on our website at investor.mylan.com.